About this trial
This study aims to evaluate how well tracheotomized patients can cough before and after their tracheostomy tube is removed. Cough strength is measured using two different tools-Peak Flow and Lorio. Researchers want to find out if the cough measurement taken before removing the tube can help predict how effective the patient's cough will be afterward. The study will also explore factors that might influence cough strength and compare the usefulness of the two tools. Additionally, it will assess how patients feel about using these devices and the role of diaphragm ultrasound in predicting cough effectiveness.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Adult patients (18 years or older)
Hospitalized in post-intensive care rehabilitation unit (SRPR) or intensive care unit (ICU)
Tracheotomized during the weaning process
Medical prescription for physiotherapy assessment
Disqualifiers
Patients who have undergone total laryngectomy
Patients with severe swallowing disorders
Patients with cognitive impairments incompatible with understanding instructions
Patients under medical decision to stop active treatments
Trial design
Single group
Treatments tested in this trial
Peak Expiratory Flow Measurement Using Peak Flow Meter and Lorio Device
DeviceThis intervention involves the use of two respiratory measurement devices to assess cough strength in tracheotomized patients: the traditional Peak Flow meter, which measures peak expiratory flow (PEF), and the Lorio device, a novel tool designed for respiratory rehabilitation with customizable training exercises. Measurements are taken at multiple time points before and after decannulation to compare accuracy, reproducibility, and patient usability.
Treatment groups
Trial outcomes
Primary outcomes
Predictive Value of Peak Expiratory Flow (PEF) Measured Before Decannulation for PEF After Decannulation in Tracheotomized Patients.
Locations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options: